In a poster study at ASCO 6/2011,they demonstrated that any decline in CA19-9 levels during chemo therapy was predictive of improved outcome in patient with advanced pancreas cancer. The range they given was (2-492,241).
On the other hand, a report I read , a 77 year old patient who had BENIGN biliary tract disease had a CA19-9 of 98628.;and a 74 yrs old cholelithiasis patient had CA19-9 of 14950.
The increase of CA19-9 could be associated with chronic hepatitis C infection,alcoholic liver disease,chronic hepatitis B infection,primary sclerosing cholangitis and primary biliary cirrhosis and other inflammatory disease .
CEA>30 and CA19-9>600 are indicative of unrectable CC on one report.
However the TREND of CA19-9 is more useful than a single CA19-9 value in
monitoring the treatment plans such as chemo or the function of the stent placement.